Selected article for: "alveolar damage and high risk"
Author: Bein, Thomas; Grasso, Salvatore; Moerer, Onnen; Quintel, Michael; Guerin, Claude; Deja, Maria; Brondani, Anita; Mehta, Sangeeta
Title: The standard of care of patients with ARDS: ventilatory settings and rescue therapies for refractory hypoxemia
  • Document date: 2016_4_4
    • ID: krpg9u1u_38
    Snippet: To diagnose sepsis resulting from invasive candidiasis, early BCs and laboratory examinations (e.g., β-d-Glucan) are recommended. Open lung biopsy should not be performed to demonstrate the presence of diffuse alveolar damage, but only considered if there is high clinical suspicion of contributive results for (risky) empirical therapy or when empirical therapy has failed [70] . Immunosuppressed patients are at high risk of invasive pulmonary asp.....
    Document: To diagnose sepsis resulting from invasive candidiasis, early BCs and laboratory examinations (e.g., β-d-Glucan) are recommended. Open lung biopsy should not be performed to demonstrate the presence of diffuse alveolar damage, but only considered if there is high clinical suspicion of contributive results for (risky) empirical therapy or when empirical therapy has failed [70] . Immunosuppressed patients are at high risk of invasive pulmonary aspergillosis. In these patients BAL galactomannan levels in CT-suspected areas are more sensitive and specific than in serum [71] . New diagnostic methods using lateral flow devices might enable bedside diagnoses in the future [72] .

    Search related documents:
    Co phrase search for related documents
    • alveolar damage and diagnostic method: 1
    • alveolar damage and diffuse alveolar damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • alveolar damage and diffuse alveolar damage presence: 1, 2, 3, 4, 5, 6
    • alveolar damage and diffuse alveolar damage presence demonstrate: 1
    • alveolar damage and high risk: 1, 2, 3, 4, 5, 6, 7
    • BAL galactomannan and flow device: 1, 2
    • BAL galactomannan and high risk: 1, 2
    • bedside diagnosis and future bedside diagnosis: 1
    • bedside diagnosis and high risk: 1, 2
    • clinical suspicion and CT suspect: 1, 2, 3
    • clinical suspicion and diagnostic method: 1, 2, 3, 4, 5, 6
    • clinical suspicion and empirical therapy: 1
    • clinical suspicion and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • CT suspect and high risk: 1
    • diagnostic method and flow device: 1
    • diagnostic method and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • diffuse alveolar damage and high risk: 1, 2, 3, 4
    • diffuse alveolar damage presence and high risk: 1
    • empirical therapy and high risk: 1, 2, 3, 4, 5, 6, 7